ArticleBlood advances2018
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- [Chinese guideline for diagnosis and treatment of lymphoplasmacytic lymphoma/Walderström macroglobulinemia (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Guideline
- A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.Blood advances · 2020Trial
- Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.British journal of haematology · 2020Trial
- A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia.Annals of medicine · 2026Article
- Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.Blood advances · 2026Article
- Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.International journal of molecular sciences · 2026Review
- Multi-omics analysis reveals a unique epigenetic signature inHaematologica · 2026Article
- Waldenström Macroglobulinemia: The Role of TP53 Mutations in Disease Progression and Therapeutic Response.Current issues in molecular biology · 2025Review
- Targeting BCL2 in Waldenström macroglobulinemia: from biology to treatment management.Frontiers in oncology · 2025Review
- How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Blood · 2024Article
- A Rare Case of Non-IgM Lymphoplasmacytic Lymphoma with Unusual Lack of Immunoglobulin Light Chain Production.The American journal of case reports · 2024Article
- Single-cell analysis of MYD88HemaSphere · 2024Article
- In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.Annals of hematology · 2024Article
- Review
- Current approach to Waldenström macroglobulinemia.Blood reviews · 2023Review
- Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.British journal of haematology · 2023Article
- The performance and applied value ofAmerican journal of nuclear medicine and molecular imaging · 2023Article
- Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.Frontiers in oncology · 2023Review
- Plasma cell neoplasms and related entities-evolution in diagnosis and classification.Virchows Archiv : an international journal of pathology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Zachary R HunterBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-1689-1691
Lian XuBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Nickolas TsakmaklisBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Maria G DemosBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Amanda KofidesBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Cristina JimenezBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Gloria G ChanBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Jiaji ChenBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Xia LiuBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Manit MunshiBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Joshua GustineBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Kirsten MeidBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Christopher J PattersonBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Guang YangBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Toni DubeauBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Mehmet K SamurHarvard Medical School, Boston, MA; and.
Jorge J CastilloBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-9490-7532
Kenneth C AndersonHarvard Medical School, Boston, MA; and.
Nikhil C MunshiHarvard Medical School, Boston, MA; and.
Steven P TreonBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-6393-6154
Dana-Farber Cancer Institute · USHarvard University · US
Funding
Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C. · 2003 to 2023
$45.0MTargeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5MNCI NIH HHS P01 CA155258NCI NIH HHS P50 CA100707
Abstract
Activating
Indexed as
AdultAgedAged, 80 and overDNA RepairEpigenesis, GeneticExome SequencingFemaleHumansMaleMiddle AgedMutationMyeloid Differentiation Factor 88NF-kappa BPolymorphism, Single NucleotideSurvival RateWaldenstrom MacroglobulinemiaMyeloid Differentiation Factor 88NF-kappa B
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.